注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Inozyme Pharma Inc是一家临床罕见病生物制药公司。该公司专注于开发影响脉管系统、软组织和骨骼的异常矿化疾病的治疗方法。其还致力于开发一种治疗外核苷酸焦磷酸酶/磷酸二酯酶1(ENPP1)和ATP结合盒亚家族C成员6(ABCC6)缺陷的罕见遗传疾病的疗法。该公司的主要候选产品INZ-701是一种可溶性、重组或基因工程融合蛋白,旨在纠正ENPP1和ABCC6缺陷导致的矿化途径缺陷。其INZ-701正处于治疗ENPP1缺乏症和ABCC6缺乏症的I/II期临床试验中。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Robert Terkeltaub | - | - | Member of Scientific Advisory Board |
Douglas A. Treco | 66 | 2020 | CEO & Chairman |
Axel Bolte | 52 | 2015 | Co-Founder, Senior Advisor & Director |
Frank Rutsch | - | - | Member of Clinical Advisory Board |
Edward Y. Skolnik | - | - | Member of Scientific Advisory Board |
Thomas O. Carpenter | - | - | Member of Clinical Advisory Board |
Yves Sabbagh | - | 2020 | Chairman of Scientific Advisory Board & Senior VP |
W. Charles O’Neill | - | 2021 | Member of Scientific Advisory Board |
Jouni Uitto | - | 2021 | Member of Scientific Advisory Board |
Paul B. Yu | - | 2021 | Member of Scientific Advisory Board |
Reinaldo M. Diaz | 70 | 2017 | Lead independent director |
Joseph P. Schlessinger | 79 | 2015 | Member of Scientific Advisory Board |
Michael A. Levine | - | - | Chairperson of Clinical Advisory Board |
Lynne Marie Sullivan | 58 | 2020 | Independent Director |
Sarah Bhagat | 37 | 2019 | Independent Director |
Robert L. Hopfner | 51 | 2018 | Independent Director |
Edward T. Mathers | 64 | 2017 | Independent Director |
Martin William Edwards | 68 | 2017 | Independent Director |
Demetrios Braddock | - | - | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核